Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

ExpreS2ion announces financial results for the third quarter of 2024

Hørsholm, Denmark, 14 November 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its third quarter and year-to-date financial results for 2024. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments: “We achieved substantial milestones in the third quarter of 2024, notably submitting the clinical trial application for our breast cancer vaccine candidate, ES2B-C001. This marks our most significant milestone for this proprietary asset. We also advanced key partnerships,

Implantica submits FDA PMA application Clinical Module 2 for RefluxStop™ for U.S. market approval

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces the submission of the second clinical module of the Premarket Approval (PMA) application to the US FDA for RefluxStop™ along with responses to the FDA’s findings from the first module.The second module submitted earlier this week for the RefluxStop™ PMA is the most crucial module of the three-module process for FDA approval. The outcome of our clinical study

Husqvarna Group recognized as diversity leader by Financial Times

Husqvarna Group is reaffirming its position as a Diversity Leader, securing the prestigious title from Financial Times and Statista for the fourth consecutive year. In the 2025 ranking Husqvarna Group is placed 141 among 850 European companies, and on a seventh position among Swedish companies.The FT-Statista Diversity Leaders ranking is based on the views of over 100,000 employees across Europe, combined with three objective indicators: - The share of women in management positions (e.g. executive committees, boards of directors, supervisory boards) - Diversity communications (e.g.

Information about the Annual Report 2023/2024

Diamyd Medical today publishes its Annual Report for 2023/24. The Company is in an expansive phase where positive feedback has been received from the US Food and Drug Administration (FDA) regarding the possibility of earlier market approval. The Annual Report is published in Swedish. The English version is expected to be published around December 6, 2024.“The past year has exceeded our highest expectations; fast track status, a successful interim analysis of the Phase 3 trial and the go ahead from the FDA for an accelerated approval procedure for Diamyd[®], says Ulf Hannelius, CEO of Diamyd

China focus as AstraZeneca reports

A falling share price and an investigation involving personnel in China take center stage as AstraZeneca releases its third-quarter report. Despite these challenges, the underlying business remains robust. Strong performance across all segments has prompted the pharmaceutical giant to raise its full-year forecast.Read the full article at biostock.se : https://www.biostock.se/en/2024/11/china-focus-as-astrazeneca-reports/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Nightingale Health Asia achieves ISO 13485:2016 certification and completes regulatory readiness to launch its blood testing service in Singapore

Nightingale Health Plc Press release 14 November 2024 at 9:15 a.m. (EET)   Nightingale Health Plc’s Singaporean subsidiary Nightingale Health Asia Pte. Ltd. (“Nightingale Health”) has been granted ISO 13485:2016 certification. ISO 13485 is the international quality management system standard for the design, production and distribution of medical devices. ISO 13485 is a requirement for medical device distribution in Singapore, and together with the earlier announced Health Sciences Authority approvals, this certification makes Nightingale Health ready to launch its blood testing

Archer Limited: New share capital registered

Hamilton, Bermuda (November 14, 2024) Reference is made to the stock exchange announcement made by Archer Limited (the "Company") on  August 16, 2024, announcing that the Company had agreed to acquire an additional 10% of the shares in Iceland Drilling from its joint venture partner Kaldbakur for USD 2.5 million (the "Share Acquisition"), to be settled through the issuance of new shares in the Company to Kaldbakur. The Company has on November 13 issued 1,174,436 new shares in the Company (the "Consideration Shares"), to enable settlement of the Share Acquisition. The Consideration

Directed share issue for the new CEO of Alisa Bank Plc

ALISA BANK PLC STOCK EXCHANGE RELEASE 14.11.2024 AT 09.10 EETThe Board of Directors of Alisa Bank Plc Corporation has today resolved a directed share issue to the new CEO, Sampsa Laine. The plan consists of a directed share issue against payment whereby the CEO subscribes maximum 1.100.000 new shares (New Shares) of Alisa Bank Plc. The purpose of the directed share issue is to engage and commit the CEO to the company´s targets and implementation of the newly launched strategy and thereby to strengthen and align the interests of the CEO, the company and its shareholders. Therefore there

Gradientech: Interim report January–September 2024

Gradientech AB (publ) interim report for Q3 2024 is now available on the company's website www.gradientech.se.Third quarter 2024 · Net sales amounted to SEK 829 thousand (53). · Net profit/loss amounted to SEK -13,399 thousand (-10,968). · Earnings per share before and after dilution were SEK -0.51 (-0.62). · Cash flow from operating activities amounted to SEK -13,906 thousand (-14,435). · Cash and cash equivalents amounted to SEK 13,142 thousand (25,873) as of September 30, 2024. · Equity amounted to SEK 21,699 thousand (40,894) as of September 30, 2024. · In July

Generative AI helps to drive 23% increase in R&D productivity at Tietoevry Care

With the help of large language models, Tietoevry Care’s software engineers are speeding up the delivery of new features and functionalities that enable health and social care providers across the Nordics to work more efficiently.As a leader in AI and data-driven care software, Tietoevry Care places great emphasis on continuously improving its product development processes. The generative AI capabilities of Microsoft GitHub Copilot play a key role in achieving this.  Tietoevry Care’s developers use GitHub Copilot for code generation, optimization, localization and more. Tasks that used

First Camp Group Interim report Q3 2024

First Camp, Scandinavia’s largest campsite chain, increased revenues in the third quarter of 2024 and presents its best quarter ever, both in terms of revenue and results.Third quarter 2024 (same quarter last year in brackets) · Total revenue of SEK 738.7 million (718.4) · Pro forma revenue increased with 5% compared to Q3 2023, excluding the retroactive electricity support received in 2023 · Pro forma Adjusted EBITDA amounted to SEK 380.9 million (367.9) · EBIT of SEK 346.2 million (325.5) · Cash flow from operating activities of SEK 67.8 million (64.0) First three

The successful brand ADOORE to open in the Victoria block in Gothenburg

At the end of February next year, ADOORE will open its first store in Gothenburg. The popular Swedish fashion brand is establishing at Södra Larmgatan 13 in the Victoria block. This is a deliberate investment for the expanding brand and an excellent addition to the fashion range right in the heart of Gothenburg.ADOORE was founded in 2017 by fashion entrepreneur Petra Tungården. After solid experience as editor-in-chief of fashion magazines and a career as a stylist, Petra felt she missed a brand that was fully focused on garments with the female silhouette in focus. She then decided to

Interim Report for 3rd Quarter 2024

Q3 2024: Revenues decreased 6.48%, EBIT increased 32.82%. First 9 months 2024: Revenue increased 5.26%, EBIT increased 37.39%Key Facts for the 3[rd] Quarter 2024 (1[st] July 2024 – 30[th] September 2024) Revenues decreased 6.48% and EBIT increased 32.82% All figures are compared to the same quarter last year if not explicitly stated otherwise. · Revenues decreased by 6.48% to €9,656,937 (€10,326,599). · EBIT increased by 32.82% to €1,452,452 (€1,093,543). · EBIT margin of 15.04% (10.59%). · Net profit increased by 40.29% to €731,306 (€521,297). · Earnings per share of

Peab builds new nursing home in Grums

Peab has been commissioned to build a new nursing home in Grums. The customer is Stiftelsen Grums kommuns hyresbostäder and the contract is worth SEK 123 million.Peab will build a new nursing home next to the existing retirement home in Grums as well as a building that connects the two. . The new construction consists of 33 apartments with pertaining common spaces and administration rooms on four floors. Peab will even create a new outdoor environment and new parking spaces. . Stiftelsen Grums kommuns hyresbostäder will lease the nursing home to Grums Municipality. "Contributing to

Interim Report for the period July – September 2024

Over 60 percent higher royalties than previous quarterEvents during the third quarter 2024 · Leqembi® received approval and launched in Hong Kong, Israel, United Arab Emirates and Great Britain · The European Medicines Agency (EMA) issued a negative opinion on the Marketing Authorisation Application for lecanemab. BioArctic's partner, Eisai, has requested a re-examination, with EMA’s decision expected shortly · Data from the lecanemab three-year extension study (OLE) demonstrated continued and increasing patient benefit, with a maintained safety profile Events after the end of

Half-year Report

FIRSTGROUP PLC HALF-YEARLY REPORT FOR THE 26 WEEKS TO 28 SEPTEMBER 2024 A robust operational and financial performance in H1 2025 leaves the Group slightly ahead of full year expectations, with the Board announcing an additional buyback programme.   Highlights   • Adjusted revenue growth to £649.6m (H1 2024 £634.8m) reflecting strong underlying performance in First Bus and good demand in First Rail open  access• Group adjusted operating profit £100.8m; H1 2024 was positively affected by an extra week of trading and a c.£13m uplift from higher than accrued

Transcom Holding AB (publ): Third quarter report 2024

Q3 2024 highlights · Revenue increased to 181.7M€ (180.6) · EBITDA excluding non-recurring items decreased to 23.9M€ (25.1) · EBITDA margin excluding non-recurring items decreased to 13.1% (13.9%) · Operating cash flow increased to 21.7M€ (9.4) · Net debt/EBITDA increased to 4.3 (3.5) January-September 2024 · Revenue increased to 551.6M€ (548.2) · EBITDA excluding non-recurring items decreased to 62.6M€ (70.6) · EBITDA margin excluding non-recurring items decreased to 11.4% (12.9%) · Operating cash flow increased to 46.7M€ (33.1) · Net debt/EBITDA

Greenfood AB (publ) gives notice that the condition for early total redemption of its outstanding notes 2021/2025 has been satisfied

Greenfood AB (publ) (the "Company") confirms that the condition contained in the conditional notice of early redemption given on 4 November 2024 to the holders of its up to SEK 1,300,000,000 senior secured sustainability-linked floating rate notes 2021/2025 with ISIN SE0017072457 issued by the Company (the "Notes") with a redemption date on 22 November 2024 has been satisfied.In the conditional notice of early redemption dated 4 November 2024 from the Company to the holders of the Notes (the "Conditional Notice of Early Redemption"), the Company notified the holders of the Notes that it

Cereno Scientific announces initiation of Multiple Ascending Dose (MAD) part of Phase I trial of the novel HDAC inhibitor CS014

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for diseases with high unmet medical needs, today announced that the Company has initiated the Multiple Ascending Dose (MAD) part of the first-in-man Phase I trial of novel HDACi CS014, after the Safety Monitoring Committee ensuring that the safety profile in the Single Ascending Dose (SAD) part is within acceptable limits. The CS014 development program is targeting rare disease Idiopathic Pulmonary Fibrosis (IPF).The MAD part (Part II) of the Phase I trial will explore safety, tolerability,

There are no items matching the current filter
There are no more items matching the current filter
Back to top